Core Viewpoint - The company, Sansure Biotech, reported a revenue of 1.244 billion yuan for the first three quarters of 2025, marking a year-on-year growth of 20.49%, with a net profit attributable to shareholders of 191 million yuan and a non-recurring net profit of 157 million yuan [1] Group 1: Financial Performance - Revenue for the first three quarters reached 1.244 billion yuan, reflecting a 20.49% increase year-on-year [1] - Net profit attributable to shareholders was 191 million yuan, while non-recurring net profit stood at 157 million yuan [1] Group 2: Strategic Initiatives - The company is advancing its "integrated diagnosis and treatment" strategy through both external acquisitions and internal innovations, enhancing the synergy of its product matrix and technology platform [1] - Sansure Biotech plans to invest 370 million yuan to establish the Hunan Jin Furong Sansure Biotech Fund Partnership, aimed at expanding its business and extending its industrial chain [1][4] Group 3: Research and Development - The company invested 237 million yuan in R&D during the first three quarters, accounting for 19.07% of its revenue [2] - Over 130 new domestic and international registration certificates were obtained, including 9 Class III medical device registration certificates, totaling over 1,800 certifications [2] Group 4: Product Development - In the respiratory field, multiple small joint detection products were approved, enhancing the "6/3+X respiratory infection nucleic acid rapid detection scheme" [2] - The company has installed over 200 integrated machines this year, with significant growth in HPV product shipments, leading the industry [3] Group 5: Investment Fund - The planned fund aims to raise 1 billion yuan, with Sansure Biotech contributing 370 million yuan, representing a 37% stake [4] - Other limited partners include government-backed funds, indicating strong recognition of the company's industry position and past achievements [6]

证券代码：688289 证券简称：圣湘生物 公告编号：2025-067 圣湘生物科技股份有限公司 关于召开2025年第四次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2025年第四次临时股东会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 17 日 14 点 30 分 召开地点：上海市闵行区华西路 680 号（圣湘生物上海产业园） （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2025 年 11 月 17 日 股东会召开日期：2025年11月17日 本次股东会采用的网络投票系统：上海证券交易所股东会网络投票系统 （二） 股东会召集人：董事会 （三） 投票方式：本次股东会所采用的表决方式是现场投票和网络投票相结合 的方式 （六） 融资融券、转融通、约定购回业务账户和沪股通投资者的投票程序 涉及融资融券、转融通业务、约定购回业务相关账户以及沪 ...

每经AI快讯，圣湘生物（SH 688289，收盘价：21.57元）10月30日晚间发布三季度业绩公告称，2025年 前三季度营收约12.44亿元，同比增加20.49%；归属于上市公司股东的净利润约1.91亿元，同比减少 2.1%。 每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ （记者 张明双） 截至发稿，圣湘生物市值为125亿元。 ...

每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ （记者 曾健辉） 每经AI快讯，圣湘生物（SH 688289，收盘价：21.57元）10月30日晚间发布公告称，圣湘生物科技股份 有限公司核心技术人员解亚平先生因个人原因申请辞任公司高级仪器研发总监等职务，辞任后将不再担 任公司任何职务。 2024年1至12月份，圣湘生物的营业收入构成为：体外诊断行业占比97.66%，其他业务占比2.34%。 截至发稿，圣湘生物市值为125亿元。 ...

Core Viewpoint - Shengxiang Bio reported a revenue of 1.244 billion yuan for the first nine months of 2025, reflecting a year-on-year growth of 20.49%, while net profit remained stable compared to the previous year [1] Group 1: Financial Performance - The company achieved a revenue of 1.244 billion yuan from January to September, marking a 20.49% increase year-on-year [1] - The net profit attributable to shareholders was 191 million yuan, with a non-recurring net profit of 157 million yuan, both remaining roughly unchanged from the same period last year [1] Group 2: Strategic Initiatives - Shengxiang Bio is implementing a "diagnosis and treatment integration" strategy, focusing on both external acquisitions and internal innovations to enhance product matrix and technical platform synergies [2] - The company has seen a rise in demand for respiratory products as the flu season approaches, with increased shipments and adequate preparations for testing needs [2] Group 3: Product Development - Multiple small joint detection products in the respiratory field have been approved this year, enriching the "6/3+X respiratory infection nucleic acid rapid detection scheme" [2] - The launch of the SUREXEVO 16A molecular POCT device in September aims to improve the efficiency and experience of respiratory pathogen detection [2] Group 4: Equipment and Automation - Shengxiang Bio has installed over 200 integrated machines this year, enhancing automation in the testing process [3] - The respiratory integrated machines have seen an addition of over 40 units, catering to the market demand during the flu season [3] Group 5: Expansion and Investment - The company is building a full-chain service capability, having acquired 100% of Zhongshan Haiji, which complements its pediatric infection diagnosis business [4] - Shengxiang Bio plans to establish a fund with partners to invest in AI medical applications and innovative medical technologies, with a target fundraising scale of 1 billion yuan [5] - The company intends to contribute 370 million yuan to the fund, representing a 37% stake, while other partners include state-owned entities [5]

圣湘生物科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 圣湘生物科技股份有限公司 2025 年第三季度报告 证券代码：688289 证券简称：圣湘生物 单位:元 币种:人民币 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比 | | 年初至报告期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期增 | 年初至报告期末 | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 375,518,504.36 | 18 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2025-066 圣湘生物科技股份有限公司 关于与专业机构共同投资设立基金暨关联交易 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为进一步推动圣湘生物科技股份有限公司（以下简称"公司"）业务拓展 及产业链延伸，增强产业协同效应，完善公司在医疗领域的综合战略布局，公司 拟与长沙圣维荣泉创业投资有限公司（以下简称"圣维荣泉"）等合伙人共同出 资设立湖南金芙蓉圣湘生物基金合伙企业（有限合伙）（暂定名，以企业注册登 记机关最终核准登记的名称为准，以下简称"基金"或"合伙企业"）（以下简称 "本次交易"或"本次投资"）。其中，公司拟作为有限合伙人认缴出资人民币 37,000 万元，出资比例 37%。 本次交易构成关联交易，未构成重大资产重组。 本次交易事项已经公司第三届董事会 2025 年第四次临时会议及第三届 董事会独立董事专门会议 2025 年第二次会议审议通过，尚需提交公司股东会审 议，与该关联交易有利害关系的关联人将放弃行使在股东会上对该议案的投票 ...

（一）核心技术人员基本情况 证券代码：688289 证券简称：圣湘生物 公告编号：2025-068 圣湘生物科技股份有限公司 关于公司核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、核心技术人员离职的具体情况 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）核心技术人员 解亚平先生因个人原因申请辞任公司高级仪器研发总监等职务，辞任后将不再担任公 司任何职务。其辞任不会对公司的技术研发、产品创新、核心竞争力与持续经营能力 产生不利影响，公司及董事会对其在任职期间为公司发展所做出的贡献表示衷心的感 谢。 解亚平先生，1981 年 9 月出生，中国国籍，无境外永久居留权，硕士研究生学历。 2007 年 3 月至 2013 年 6 月，任职于台达电子武汉研发中心，担任主任工程师主管职 务；2013 年 6 月至 2014 年 6 月，任职于武汉友芝友生物制药，担任高级经理职务； 2014 年 6 月至 2015 年 1 月，任职于中国平安，担任高级产品经理职务；2015 年 1 月 至 202 ...

Market Overview - The Shanghai Composite Index closed at 3913.76 points, slightly down by 0.07%, with a total trading volume of 1.69 trillion yuan [1] - A total of 53 A-shares have surpassed their annual moving average, indicating a positive market sentiment [1] Notable Stocks - The stocks with the largest deviation from the annual line include: - Zhu Mian Group (600185) with a deviation rate of 8.66% and a daily increase of 10.08% [1] - Wanda Bearings (920002) with a deviation rate of 8.27% and a daily increase of 13.50% [1] - China Railway Construction (300374) with a deviation rate of 8.10% and a daily increase of 11.87% [1] - Other stocks that have just crossed the annual line with smaller deviation rates include: - Yabenn Chemical, Yangtze Power, and High-tech Development [1] Trading Activity - The trading turnover rates for notable stocks include: - Wanda Bearings at 12.02% and China Railway Construction at 31.44% [1] - The latest prices for these stocks are as follows: - Zhu Mian Group at 6.88 yuan, Wanda Bearings at 117.26 yuan, and China Railway Construction at 18.94 yuan [1]

Core Viewpoint - As of October 22, 2023, 53 A-shares have crossed the annual line, indicating a potential bullish trend in the market despite a slight decline in the Shanghai Composite Index [2][3] Group 1: Market Overview - The Shanghai Composite Index is at 3905.69 points, with a decrease of 0.27% [2] - The total trading volume of A-shares today is 13846.11 billion yuan [2] Group 2: Stocks Crossing the Annual Line - Notable stocks with significant deviation rates include: - China Railway Construction (中铁装配) with a deviation rate of 9.52% and a price increase of 13.35% [3] - Zhuhai Free Trade Zone Group (珠免集团) with a deviation rate of 8.66% and a price increase of 10.08% [3] - Wanda Bearings (万达轴承) with a deviation rate of 6.93% and a price increase of 12.09% [3] - Other stocks that have just crossed the annual line with smaller deviation rates include: - Debi Group (德必集团) and Huaren Pharmaceutical (华仁药业) [2][3]